We support a UN instrument to end plastics pollution through a harmonized, global approach that also prioritizes patient safety and safeguards access to medicinal and medical products. Plastics pollution is a threat to both the environment and human health, with impacts across the plastics value chain. It is important that the treaty takes an approach...
Read moreThe innovative pharmaceutical industry, represented by IFPMA, INTERFARMA and FIFARMA reiterates its commitment to the G20 health priorities, reaffirmed in the Rio de Janeiro Declaration.
Read moreOn 4 November 2024 in Geneva, IFPMA delivered a statement at the twelfth meeting of the Intergovernmental Negotiating Body (INB).
Read moreOn the conclusion of the COP16 negotiations on proposals to include digital sequence information (DSI) within the scope of the Convention of Biodiversity (CBD), IFPMA delivered a Statement
Read moreOn 31 October 2024 in Copenhagen, Denmark, IFPMA delivered a statement at the 74th WHO Regional Committee for Europe on harnessing innovation for public health in the WHO European Region 2025-2030.
Read moreOn 31 October 2024 in Copenhagen, Denmark, IFPMA and EFPIA delivered a statement at the 74th Regional Committee for Europe on the framework for resilient and sustainable health systems in the WHO European Region.
Read moreOn 29 October 2024 in Copenhagen, Denmark, IFPMA and EFPIA delivered a statement at the 74th WHO Regional Committee for Europe on the WHO/Europe Access to Novel Medicines Platform.
Read morePhilip Tagboto, co-chair of the IFPMA Africa Engagement Committee, shares reflections from a multistakeholder forum organized by AREPI and IFPMA uniting various stakeholders from Ghana’s healthcare and pharmaceutical sectors.
Read more
On 21 October 2024 in Cali, Colombia, IFPMA delivered an opening statement at the 16th meeting of the Conference of the Parties to the Convention on Biological Diversity.
Read moreAccording to the WHO, non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Of these, 17 million people die from NCDs before the age of 70. Eighty-six percent of these premature deaths occur in low- and middle-income countries (LMICs), whose health systems are the least equipped to deliver...
Read more
On 16 October 2024 in Geneva, IFPMA delivered a statement at the 36th meeting of WIPO’s Standing Committee on Patents:, on technology transfer.
Read moreOn 16 October 2024 in Geneva, IFPMA delivered a statement at the 36th meeting of WIPO’s Standing Committee on Patents: Patents and Health.
Read more